Suscribirse

Peroxisome proliferator activated receptor-γ modulates reactive oxygen species generation and activation of nuclear factor-κB and hypoxia-inducible factor 1⍺ in allergic airway disease of mice - 17/08/11

Doi : 10.1016/j.jaci.2006.03.021 
Kyung Sun Lee, PhD a, b, c, , So Ri Kim, MD a, b, c, , Seoung Ju Park, MD a, b, c, Hee Sun Park, MD, PhD a, b, c, Kyung Hoon Min, MD a, b, c, Sun Mi Jin, BS b, c, Moon Kyu Lee, MD, PhD f, Uh Hyun Kim, MD, PhD d, e, Yong Chul Lee, MD, PhD a, b, c,
a From the Department of Internal Medicine 
b Airway Remodeling Laboratory 
c Research Center for Allergic Immune Diseases 
d Department of Biochemistry 
e Institute of Cardiovascular Research, Chonbuk National University Medical School, Jeonju 
f Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 

Reprint requests: Yong Chul Lee, MD, PhD, Department of Internal Medicine, Chonbuk National University Medical School, San 2-20, Geumam-dong, Jeonju, 561-180, Korea.

Jeonju and Seoul, Korea

Abstract

Background

Reactive oxygen species (ROSs) play a crucial role in the pathogenesis of airway inflammation. Peroxisome proliferator activated receptor (PPAR)-γ is also involved in airway inflammation. We have demonstrated that the administration of PPARγ agonists or adenovirus carrying PPARγ cDNA (AdPPARγ) reduced bronchial inflammation and airway hyperresponsiveness. However, the effects of PPARγ on ROS generation in conditions associated with airway inflammation have not been clarified.

Objective

This study aimed to investigate the effects of the PPARγ on ROS generation in allergic airway disease of mice.

Methods

We have used a female C57BL/6 mouse model for allergic airway disease to determine the role of PPARγ.

Results

In this study with an ovalbumin-induced murine model of allergic airway disease, the increased ROS generation and the increased expression of TH2 cell cytokines, adhesion molecules, chemokines, and vascular endothelial growth factor in lungs after ovalbumin inhalation were significantly reduced by the administration of PPARγ agonists or AdPPARγ. We also showed that the increased nuclear factor-κB and hypoxia-inducible factor 1⍺ levels in nuclear protein extracts of lung tissues after ovalbumin inhalation were decreased by the administration of PPARγ agonists or AdPPARγ.

Conclusion

These results indicate that the effects of PPARγ are mediated by the modulation of ROS generation and activation of redox-sensitive transcription factor nuclear factor-κB and HIF-1⍺ in allergic airway disease of mice.

Clinical implications

Thus, these findings provide a pivotal molecular mechanism for the use of PPARγ agonists to prevent and/or treat asthma and other airway inflammatory disorders.

El texto completo de este artículo está disponible en PDF.

Key words : Asthma, HIF-1⍺, NF-κB, oxidative stress, peroxisome proliferator activated receptor γ

Abbreviations used : AdPPARγ, BAL, EBD, HIF, ICAM-1, NF-κB, PPAR, ROS, VCAM-1, VEGF


Esquema


 Supported by grants from the National Research Laboratory Program and from the Medical Science and Engineering Research Center of the Korea Science and Engineering Foundation (R13-2002-038-01004-0), Republic of Korea.
Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.


© 2006  American Academy of Allergy, Asthma and Immunology. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 118 - N° 1

P. 120-127 - juillet 2006 Regresar al número
Artículo precedente Artículo precedente
  • Montelukast regulates eosinophil protease activity through a leukotriene-independent mechanism
  • Anick Langlois, Claudine Ferland, Guy M. Tremblay, Michel Laviolette
| Artículo siguiente Artículo siguiente
  • Short course of systemic corticosteroids in sinonasal polyposis: A double-blind, randomized, placebo-controlled trial with evaluation of outcome measures
  • Pravin Hissaria, William Smith, Peter J. Wormald, James Taylor, Mathew Vadas, David Gillis, Frank Kette

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.